White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹1.31 – ₹117.65 · fair‑value band ₹3.77 – ₹8.56 · the ₹38.88 price screens above the ₹6.85 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Fischer Medical Ventures Ltd (FISCHER) currently trades at ₹38.88, while our model-based Fair Value estimate is ₹6.85, implying the stock looks roughly 82.4% overvalued today. The Quality Score stands at 40/100 (below-average quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Fischer Medical Ventures Ltd generated revenue of ₹3.1B at a net margin of 10.1%. Revenue grew 98.7% year over year. It earns a return on equity of 8.6%. Net debt stands at ₹605M. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹3.77 (bear case) to ₹8.56 (bull case); at ₹38.88, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 69% below its 52-week high and 25% above its 52-week low, currently below its 200-day average. For context, the median of 10 Industrials peers we cover trades at 107% fair-value upside, at -82%, FISCHER screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
Note: the current price implies far more future growth than the conservative anchors of our models allow (base growth is deliberately capped, we do not regard such extreme rates as sustainable). Our models are not designed for expectations this high; that is why the individual models scatter extremely (₹0.0700 to ₹22.47). Read the values as a conservative anchor, not as a price target.
ModelBear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence
Highest evidence
Residual Income₹4.87₹5.22₹6.1776
ROIC Compounder₹5.43₹7.01₹9.2372
Gordon GGM₹0.0400₹0.0800₹0.130070
All 17 models by family
DCF Models
Owner Earnings₹8.02₹18.02₹39.0131
Earnings-Based
Graham-Dodd₹3.22₹22.47₹31.5454
Lynch FV₹11.61₹16.59₹21.5650
PEG = 1.0₹11.61₹16.59₹21.5646
EPV₹5.43₹6.30₹7.0759
Dividend Discount
Gordon GGM₹0.0400₹0.0800₹0.130070
DDM Multi-Stage₹0.0400₹0.0700₹0.080061
Multiples
P/E Multiple₹7.46₹9.95₹12.4463
P/S Multiple₹6.04₹8.06₹10.0758
P/B Multiple₹6.04₹8.06₹10.0755
EV/EBIT₹7.99₹10.59₹13.2053
EV/EBITDA₹6.60₹8.73₹10.8754
EV/Revenue₹5.75₹8.14₹10.5343
Asset-Based
NCAV (Graham)₹2.94₹3.93₹5.8750
Economic Profit
Residual Income₹4.87₹5.22₹6.1776
ROIC Compounder₹5.43₹7.01₹9.2372
Growth Earnings
Growth-Adj P/E₹15.19₹21.70₹28.2168
Widest divergence: Growth Earnings (₹21.70) versus Dividend Discount (₹0.0700). Highest evidence: Residual Income (76).
Notify me when FISCHER reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Revenue (TTM)₹3.1B
Revenue growth (YoY)+98.7%
Net margin10.1%
Return on equity8.6%
Free cash flow−₹1.0BFY2026
P/E ratio86.4
More key figures
Operating margin0.1%
EPS (TTM)₹0.4500
Dividend yield0.1%
EPS growth (YoY)+4,120%
Net debt₹605MFY2026
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Overall quality40/100
Of which business quality 41
· Market factors (momentum, volatility) 30
Profitability37
Margins and returns on capital today
Quality Growth89
Are margins and returns improving?
Cashflow0
Earnings quality: real cash, not paper profit
Fin. Strength77
Balance sheet, leverage, solvency risk
Investment50
Disciplined investing over empire-building
Low Volatility57
Calm price path (market factor)
Momentum26
Price trend over the last 3–12 months (market factor)
52W Momentum4
Distance to the 52-week high (market factor)
Net Issuance0
Buybacks instead of dilution
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Fischer Chemic Limited trades in laboratory chemicals and machineries in India. It also provides AMC and consultancy services. The company was incorporated in 1993 and is based in Mumbai, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Fischer Medical Ventures Ltd reported revenue of ₹3.1B in FY2026 versus ₹0 in FY2022. Reported net income was ₹310M in FY2026.
Growth Quality 51/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2026)
₹3.1B
Latest YoY
+178.8%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+1,097.9%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+351.2%
Avg. growth/yr (12Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Fischer Medical Ventures Ltd Fair Value". https://www.fairvalue-calculator.com/stock/FISCHER
Peer Group
Industrials · 5431 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Professional & Commercial Services” was too small, so the broader sector is used.)
Quality Score40 · Bottom 25%
Fair Value upside−82% · Bottom 25%
Return on equity (TTM)9% · Above median
Return on assets4% · Above median
Net margin (TTM)10% · Top 25%
Operating margin (TTM)0% · Bottom 25%
Revenue growth99% · Top 25%
Dividend yield (TTM)0.1% · Bottom 25%
Debt / equity0.00× · Lower than 75% of peers
Valuation Multiples vs Industrials median · lower = cheaper
P/E (TTM)86.4× · Pricier than 75% of peers
P/B6.69× · Pricier than 75% of peers
P/S (TTM)8.34× · Pricier than 75% of peers
EV/EBITDA62.8× · Pricier than 75% of peers
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
This stockSector peers
VALUE0· sector 7
FUTURE100· sector 23
PAST35· sector 27
HEALTH100· sector 94
DIVIDEND3· sector 35
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Professional & Commercial Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
Is Fischer Medical Ventures Ltd (FISCHER) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of ₹6.85 versus a price of ₹38.88, about −82% (overvalued).
What is the fair value of FISCHER?
Our model-based fair value for Fischer Medical Ventures Ltd is ₹6.85 (as of Aug 13, 2026), built from audited fundamentals. The current price: ₹38.88.
What is the quality score of FISCHER?
Fischer Medical Ventures Ltd has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Fischer Medical Ventures Ltd (FISCHER)?
Fischer Medical Ventures Ltd reported trailing-twelve-month revenue of about ₹3.1B (latest available figure, as of Aug 13, 2026).
What is the net profit margin of FISCHER?
The net profit margin of Fischer Medical Ventures Ltd is about 10.1%, meaning it keeps roughly 10.1% of revenue as net income. Based on the latest reported figures.
Does Fischer Medical Ventures Ltd pay a dividend?
Fischer Medical Ventures Ltd currently shows a dividend yield of about 0.13% relative to its recent price (as of Aug 13, 2026).
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
14 days Pro free · no card
Track Fischer Medical Ventures Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
or
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
